Tags

Type your tag names separated by a space and hit enter

TMC207 becomes bedaquiline, a new anti-TB drug.
Future Microbiol 2013; 8(9):1071-80FM

Abstract

TB still represents a serious public health problem. The latest reports estimate an incidence of 8.7 million cases in 2011 and 1.4 million deaths. Drug resistance contributed an estimated 630,000 cases of multidrug-resistant TB, making control of the disease harder. Recent reports show cases of TB that were almost resistant to all available antibiotics. Therefore, there is an urgent need to develop new anti-TB drugs with the potential of reducing the current length of treatment. Bedaquiline, formerly TMC207, is a new diarylquinoline antibiotic with specific activity against Mycobacterium tuberculosis and several nontuberculous mycobacteria. It acts by inhibiting ATP synthase, interfering with the energy generation needed by the bacterial cell. Based on clinical evaluations for safety, tolerability and efficacy, bedaquiline has recently received accelerated approval for the treatment of pulmonary multidrug-resistant TB in adults. This article will review the main aspects related to the chemistry, microbiology, pharmacology, efficacy and tolerability of bedaquiline.

Authors+Show Affiliations

Laboratory of Microbiology, Department of Biochemistry & Microbiology, Faculty of Sciences, Ghent University, 9000, Ghent, Belgium.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24020736

Citation

Palomino, Juan Carlos, and Anandi Martin. "TMC207 Becomes Bedaquiline, a New anti-TB Drug." Future Microbiology, vol. 8, no. 9, 2013, pp. 1071-80.
Palomino JC, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol. 2013;8(9):1071-80.
Palomino, J. C., & Martin, A. (2013). TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiology, 8(9), pp. 1071-80. doi:10.2217/fmb.13.85.
Palomino JC, Martin A. TMC207 Becomes Bedaquiline, a New anti-TB Drug. Future Microbiol. 2013;8(9):1071-80. PubMed PMID: 24020736.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - TMC207 becomes bedaquiline, a new anti-TB drug. AU - Palomino,Juan Carlos, AU - Martin,Anandi, PY - 2013/9/12/entrez PY - 2013/9/12/pubmed PY - 2014/4/1/medline SP - 1071 EP - 80 JF - Future microbiology JO - Future Microbiol VL - 8 IS - 9 N2 - TB still represents a serious public health problem. The latest reports estimate an incidence of 8.7 million cases in 2011 and 1.4 million deaths. Drug resistance contributed an estimated 630,000 cases of multidrug-resistant TB, making control of the disease harder. Recent reports show cases of TB that were almost resistant to all available antibiotics. Therefore, there is an urgent need to develop new anti-TB drugs with the potential of reducing the current length of treatment. Bedaquiline, formerly TMC207, is a new diarylquinoline antibiotic with specific activity against Mycobacterium tuberculosis and several nontuberculous mycobacteria. It acts by inhibiting ATP synthase, interfering with the energy generation needed by the bacterial cell. Based on clinical evaluations for safety, tolerability and efficacy, bedaquiline has recently received accelerated approval for the treatment of pulmonary multidrug-resistant TB in adults. This article will review the main aspects related to the chemistry, microbiology, pharmacology, efficacy and tolerability of bedaquiline. SN - 1746-0921 UR - https://www.unboundmedicine.com/medline/citation/24020736/TMC207_becomes_bedaquiline_a_new_anti_TB_drug_ L2 - http://www.futuremedicine.com/doi/full/10.2217/fmb.13.85?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -